---
title: "RemeGen climbs 5% in Hong Kong trading on mRNA vaccine catalyst"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296420842.md"
description: "RemeGen climbs 5% in HK trading to HK$81.85 on mRNA vaccine catalyst and strong H1 earnings outlook."
datetime: "2026-08-20T01:39:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296420842.md)
  - [en](https://longbridge.com/en/news/296420842.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296420842.md)
generator: "portal-rs"
---

# RemeGen climbs 5% in Hong Kong trading on mRNA vaccine catalyst

RemeGen Co. (9995.HK) climbed **5%** during Hong Kong trading to **HK$81.85**.

The rally tracked a broader biotech rally after Moderna and Merck reported positive Phase 3 results for their personalized mRNA cancer vaccine, lifting Hong Kong-listed biotech names. RemeGen's expected first-half net profit of roughly **4.7 billion yuan**, driven largely by the upfront payment from the RC148 licensing deal, also underpinned sentiment.

### Related Stocks

- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)

## Related News & Research

- [RemeGen files HKEX next-day disclosure return reporting share buyback on Shanghai exchange at RMB 113.43 per share](https://longbridge.com/en/news/298706225.md)
- [RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products](https://longbridge.com/en/news/297779978.md)
- [Flam raises $40 million Series B for interactive AI content](https://longbridge.com/en/news/299038769.md)
- [China’s AlphaPai raises $50M Series B for AI investment-research assistant](https://longbridge.com/en/news/299031736.md)
- [SFC Issues Guidance on How I-Banks Should Cooperate in Raids; 8 Searches Conducted This Yr; Focus on IPO Fund Misappropriation and Listing Abuse: Wire](https://longbridge.com/en/news/298714382.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**